Oncotarget

Research Papers:

Survival outcomes of CD34+CD38LSCs and their expression of CD123 in adult AML patients

Asmaa M. Zahran, Sanaa Shaker Aly, Amal Rayan _, Omnia El-Badawy, Maged Abdel Fattah, Arwa Mohammed Ali, Hala M. ElBadre and Helal F. Hetta

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2018; 9:34056-34065. https://doi.org/10.18632/oncotarget.26118

Metrics: PDF 1228 views  |   HTML 1987 views  |   ?  


Abstract

Asmaa M. Zahran1, Sanaa Shaker Aly2, Amal Rayan3, Omnia El-Badawy4, Maged Abdel Fattah5, Arwa Mohammed Ali5, Hala M. ElBadre6 and Helal F. Hetta4

1Clinical Pathology Department, South Egypt Cancer Institute, Assiut University, Assiut, Egypt

2Clinical and Chemical Pathology Department, Faculty of Medicine, South Valley University, Qena, Egypt

3Clinical Oncology Department, Faculty of Medicine, Assiut University, Assiut, Egypt

4Medical Microbiology and Immunology Department, Faculty of medicine, Assiut University, Assiut, Egypt

5Medical Oncology Department, South Egypt Cancer Institute, Assiut University, Assiut, Egypt

6Medical Biochemistry Department, Faculty of Medicine, Assiut University, Assiut, Egypt

Correspondence to:

Amal Rayan, email: amal3774rayan@gmail.com

Keywords: acute myeloid leukemia; CD34+CD38-LSCs; CD34+CD38-CD123+LSCs; disease free survival; overall survival

Received: April 23, 2018    Accepted: July 31, 2018    Published: September 25, 2018

ABSTRACT

Background and aim: Acute myeloid leukemia (AML) is one of the most common leukemias in adults. AML is generally regarded as a stem cell disease characterized by an accumulation of undifferentiated and functionally heterogeneous populations of cells, The aim of the present study was to identify leukemia stem cells in patients with AML and their correlations with treatment outcomes namely remission status, disease free survival, and overall survival.

Results: The mean percentages of CD34+CD38- and CD34+CD38low/−CD123+ LSCs were 2.2± 0.4and 22.3± 2.6, respectively. The percentages of CD34+cells, CD34+CD38- and CD34+CD38low/−CD123+ LSCs were significantly lower in AML patients with complete remission than those without complete response (P<0.001, P<0.004, P<0.001 respectively). The mean OS of all study patients was 20.03±1.2 months while the median OS was 21 months (95% CI=18.32-21.48). The mean DFS was 16.96±1.02 months and the median was 18 months (95% CI=8.9-11.4). DFS and OS were significantly higher among those who achieved CR than those without CR. In addition, there were significant negative effects of WBCs, CD34+cells, CD34+CD38- and CD34+CD38-CD123+LSCs on DFS and OS.

Patients and methods: We investigated 30 patients with newly diagnosed AML; all patients underwent complete history taking, and thorough physical and clinical examination, complete blood count. Peripheral smears and bone marrow aspirates were also examined. Cytochemistry and immunophenotyping of leukemic cells were performed routinely in bone marrow using monoclonal antibodies. Flow cytometry was used to analyze leukemia stem cells and their expression of CD123.

Conclusion: Our study elucidated that CD34+CD38-LSCs, with or without CD123+LSCs phenotype was present in a significant proportion of AML patients and it could be responsible for resistance to traditional treatments, and high percentage of MRD that was translated into significantly high number of non CR, poor DFS, and OS.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 26118